Chongqing Qingyutang Pharmaceutical Co. Ltd.

Main study objectives To investigate the bioequivalence of the test formulation of Lebrexan tablets (5 mg, produced by Qingyutang Pharmaceutical Co., Ltd., Fu'an Pharmaceutical Group) and the reference formulation (trade name: DAYVIGO®, 5 mg, certified by AEISHI Co., Ltd.) after a single oral administration in healthy subjects under fasting state. Secondary study objectives To observe the safety of the test formulation and the reference formulation of Lebrexan tablets in healthy subjects.

Main purpose: This study uses Sulindac Tablets (Specification: 0.2 g) produced and owned by Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, Sulindac Tablets (Specification: 200 mg, trade name: Sulindac) owned by WATSON LABORATORIES INC is used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: Observe the safety of the test preparation Sulindac Tablets and the reference preparation Sulindac Tablets (Sulindac) in healthy subjects.

A single-center, randomized, open-label, single-dose, two-formulation, two-period crossover human bioequivalence study of cefditoren pivoxil tablets in healthy Chinese subjects.